July 30, 2009 - Shares of General Electric Company (NYSE:GE) are surging more then 6% this morning to $13.07 as Goldman Sachs has upgraded the stock. GE stock has been added to the conviction buy list.
I am watching out for the next resistance level which is located at $14.43. If this level is broken, GE shares can trading well over $15.
Goldman upgraded General Electric citing reports that US House Financial Services Chairman Barney Frank has indicated regulatory reform will not require a separation of GE Capital. Goldman slaps a Target to $15 per share from $13 per share.
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Showing posts with label Ge stock news. Show all posts
Showing posts with label Ge stock news. Show all posts
Thursday, July 30, 2009
Tuesday, June 30, 2009
Geron GERN Stock News June 30, 2009
A major stem cell stock has received huge news this morning ( 6/30/09 ). Geron Corporation (GERN) is announcing an agreement with General Electric Co. (GE). Discuss GERN
Discuss Stocks - http://stockstobuy.org
GERN Stock News - 6/30/09
GE Healthcare and Geron Announce Exclusive Global Agreement to Commercialize Stem Cell Drug Discovery Technologies
GE Healthcare, a unit of General Electric Company (NYSE:GE), and Geron Corporation (Nasdaq:GERN) today announced that they have entered into a global exclusive license and alliance agreement to develop and commercialize cellular assay products derived from human embryonic stem cells (hESCs) for use in drug discovery, development and toxicity screening. The program will use stem cells derived from hESC lines listed on the NIH Human Pluripotent Stem Cell Registry. Financial terms are not being disclosed.
“This agreement marks a further step in GE Healthcare’s cell technology strategy aimed at addressing the potential of stem cell applications in the drug discovery and therapy markets,” said Konstantin Fiedler, General Manager, Cell Technologies, GE Healthcare. “Combining GE Healthcare’s reach into the drug discovery and research markets, as well our expertise in cell manufacturing, with Geron’s expertise and IP in hESCs, means that together, we will be able to accelerate the development of hESC-derived products for drug discovery and development.”
Full Article
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Discuss Stocks - http://stockstobuy.org
GERN Stock News - 6/30/09
GE Healthcare and Geron Announce Exclusive Global Agreement to Commercialize Stem Cell Drug Discovery Technologies
GE Healthcare, a unit of General Electric Company (NYSE:GE), and Geron Corporation (Nasdaq:GERN) today announced that they have entered into a global exclusive license and alliance agreement to develop and commercialize cellular assay products derived from human embryonic stem cells (hESCs) for use in drug discovery, development and toxicity screening. The program will use stem cells derived from hESC lines listed on the NIH Human Pluripotent Stem Cell Registry. Financial terms are not being disclosed.
“This agreement marks a further step in GE Healthcare’s cell technology strategy aimed at addressing the potential of stem cell applications in the drug discovery and therapy markets,” said Konstantin Fiedler, General Manager, Cell Technologies, GE Healthcare. “Combining GE Healthcare’s reach into the drug discovery and research markets, as well our expertise in cell manufacturing, with Geron’s expertise and IP in hESCs, means that together, we will be able to accelerate the development of hESC-derived products for drug discovery and development.”
Full Article
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Subscribe to:
Posts (Atom)
